Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Open Angle Glaucoma, Pseudoexfoliation G...
Phase NA
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to perform trabeculopuncture a test to determine the distal outflow tract function to predict the success of ab interno trabeculectomy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Trabeculopuncture — Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.

Primary Outcomes

  • IOP (before and two hours after trabeculopuncture, one and four weeks postoperatively (after ab interno trabeculectomy), and three months postoperatively)
  • Outflow facility (before and two hours after trabeculopuncture, one and four weeks postoperatively (after ab interno trabeculectomy), and three months postoperatively)
  • Surgical success (at month three)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-13
Completion: 2026-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wuerzburg University Hospital
Principal Investigators:
  • Daniel Kampik, MD, PhD (PRINCIPAL_INVESTIGATOR) - Department of Ophthalmology University Hospital Würzburg
Contact Information
Study Contact:
Raoul Verma-Fuehring, MD
+49 93120120662
vermafuehr_R@ukw.de
Raoul Verma-Führing, MD
0049 93120120662
vermafuehr_R@ukw.de
Uniklinikum Würzburg
Interventions
  • Diagnostic Test: Trabeculopuncture — Trabeculopuncture is performed with a Nd:YAG laser on the trabecular meshwork. Four punctures are created along the 180° nasal trabecular meshwork.
Study Locations (1 sites)
Uniklinikum Würzburg, Würzburg, Bavaria 97080 Germany
Eligibility Criteria
Inclusion Criteria: * individuals ≥ 18 years of age * clinical diagnosis of: primary open angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma * uncontrolled intraocular pressure (IOP) with maximally tolerated medical therapy * progressive thinning of retinal nerve fiber layer assessed by Spectral domain optical coherence tomography (p \< 0.05) * progression of visual field defects * visually significant cataract and indication to reduce IOP or glaucoma medication burden Exclusion Criteria: * clinical diagnosis of neovascular glaucoma, angle-closure glaucoma, uveitic glaucoma, neovascular glaucoma * prior glaucoma surgery * preexisting conditions affecting the episcleral venous pressure including Grave's ophthalmopathy, Sturge-Weber syndrome, Arteriovenous fistulas (carotid-cavernous fistula)
Conditions Cirrhosis, Esophageal Varices
Phase PHASE4
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol non-responders. It will also learn about the safety of carvedilol combined with EVL in patients with cirrhosis. The main questions it aims to answer are: Whether carvedilol plus EVL is more effective than carvedilol alone in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol. What medical problems do participants have when taking carvedilol or taking carvedilol combined with undergoing EVL? Researchers will compare the efficacy and safety of carvedilol with or without EVL in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol. Participants will: Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol, or Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable). Visit the clinic once every 2-3 months for checkups and tests. Keep a diary of their vital signs (SBP, DBP, and HR) as well as symptoms.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Carvedilol plus endoscopic variceal ligation — Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
  • Drug: Carvedilol alone — Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).

Primary Outcomes

  • Esophageal variceal bleeding (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01-06
Completion: 2030-10
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taipei Veterans General Hospital, Taiwan
Contact Information
Study Contact:
Tsung-Chieh Yang, MD
886-2-28712121
tcyang@vghtpe.gov.tw
Ming-Chih Hou, MD
886-2-28712121
mchou@vghtpe.gov.tw
Tsung-Chieh Yang, MD
886-2-28712121
tcyang@vghtpe.gov.tw
Taipei Veterans General Hospital
Interventions
  • Other: Carvedilol plus endoscopic variceal ligation — Take carvedilol every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol.
  • Drug: Carvedilol alone — Take carvedilol alone every day (start from 6.25 mg/d and then titrate to 12.5 mg/d if tolerable).
Study Locations (1 sites)
Taipei Veterans General Hospital, Taipei, 11217 Taiwan
Eligibility Criteria
Inclusion Criteria: \- Cirrhotic patients with esophageal varices who, after carvedilol treatment, continue to experience variceal enlargement or develop new red color signs. Exclusion Criteria: * Age under 18 or over 90 years. * History of esophageal variceal bleeding. * Previous treatment for esophageal varices, including endoscopic variceal ligation, endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, or surgery. * Contraindications to non-selective beta-blockers, including severe atrioventricular block, chronic obstructive pulmonary disease (COPD), asthma, uncontrolled diabetes mellitus, or severe peripheral artery disease. * Presence of end-stage organ diseases, including hepatocellular carcinoma or other terminal cancers, heart failure, or renal failure. * Pregnant women. * Refusal to participate in the study.
Conditions Arterial Hypertension, Resistant Hyperte...
Phase EARLY_PHASE1
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Beetroot extract — Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
  • Dietary Supplement: Placebo — The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.

Primary Outcomes

  • Assessment of blood pressure evolution (60 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-11-01
Completion: 2026-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Cardiology, Laranjeiras, Brazil
Contact Information
Study Contact:
EDUARDO TIBIRICA, MD, PhD
+55-21-99914-6075
etibi@uol.com.br
Eduardo Tibirica
2125921265
eitib@uol.com.br
National Institute of Cardiology
Interventions
  • Dietary Supplement: Beetroot extract — Beetroot extract powder supplementation with 400mg of nitrate per dose in the amount of 10g per day orally will be used in the group.
  • Dietary Supplement: Placebo — The placebo will be administered as a colored and flavored isocaloric supplement composed of maltodextrin.
Study Locations (1 sites)
National Institute of Cardiology, Rio de Janeiro, 21040-360 Brazil
Eligibility Criteria
Inclusion Criteria: * Resistant hypertension, with a diagnosis described in the medical record, without changing medications or increasing doses in the last 30 days. Exclusion Criteria: * neoplasms * heart failure * use of medications with nitrate in their formula * patients undergoing renal denervation
Conditions Gestational Diabetes, Hypertensive Disor...
Phase NA
Enrollment 864
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Hypertensive disorders during pregnancy (HDP) and gestational diabetes (GDM) are among the leading complications in pregnancy, significantly contributing to global maternal and fetal morbidity and mortality. (1,2,3) Effective management of HDP and GDM hinges on regular monitoring of blood pressure (BP) and blood glucose (BG) to ensure adequate control and timely interventions for maternal and fetal well-being. Telemonitoring offers a promising and cost-effective alternative by enabling pregnant individuals to monitor BP and BG at home and share real-time results with healthcare providers, facilitating informed clinical decision-making and timely interventions. Here the investigators propose to conduct a Hybrid Type II Effectiveness-Implementation Randomized Controlled Trial (RCT) to assess the effectiveness and evaluate the implementation of the MOM-HD (Mobile-based Obstetric Monitoring for Hypertension and/or Diabetes) program, a mobile app-based perinatal telemonitoring program, in real-world clinical settings in Nepal. To address the study aims, the investigators will recruit 864 women who are newly diagnosed with HDP and GDM from three metropolitan hospitals and randomly assign them to either (i) MOM-HD + standard care or (ii) standard care alone, from enrolment in pregnancy to 6 weeks postpartum. Primary and secondary clinical outcomes will be assessed at delivery, and at 6 weeks postpartum. The investigators hypothesize that compared to standard care, the use of MOM-HD in addition to standard care will result in lower systolic BP levels, lower incidence rate for the composite adverse perinatal outcome of either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery or labor induction, and lower proportion of days with elevated systolic BP or BG readings between recruitment and 6 weeks postpartum. A convergent mixed-methods approach will be used to assess implementation and maintenance outcomes using the RE-AIM framework (4), and economic sustainability will be assessed by collecting primary cost data.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: MOM-HD — Participants will receive education and training on proper BP and/or BG monitoring and will be provided a BP monitor and/or glucometer with strips. They will be asked to use the MOM-HD mobile app to measure and record daily BP (until 6 weeks postpartum) and, for women with GDM, fasting and 2-hour postprandial BG (until delivery). Readings are automatically uploaded via Bluetooth to a provider portal and reviewed daily by a nurse. Participants will receive automated reminders, instant feedback on readings, and educational materials via the app. They will participate in biweekly tele-visits with a nurse to review readings, discuss symptoms, and receive counseling on lifestyle, diet, and care plans.
  • Other: Standard Care — Pregnant women with HDP and GDM will receive standard antenatal care, which includes more frequent hospital visits (6-8 extra), ultrasound, urine dipstick, BP/BG monitoring with paper record booklets, dietary and physical activity counseling, and OB/GYN follow-up. GDM patients will consult with a dietitian and physical therapist. Postpartum follow-up includes BP/BG testing at 6 weeks.

Primary Outcomes

  • Mean systolic BP from recruitment to delivery (continuous) (Post-treatment (at delivery))
  • Rate of composite adverse perinatal outcome (categorical; either perinatal loss, neonatal intensive care unit admission, primary cesarean delivery, preterm birth ) (Post-treatment (at delivery))
  • Proportion of days with elevated blood pressure (BP) or blood glucose (BG) readings (above clinical target ranges) between recruitment and delivery (continuous) (Post-treatment (at delivery))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-30
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 864 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rutgers, The State University of New Jersey
Collaborators: Dhulikhel Hospital, Institute for Implementation Science and Health
Principal Investigators:
  • Shristi Rawal, PhD (PRINCIPAL_INVESTIGATOR) - Rutgers School of Health Professions
Contact Information
Study Contact:
Shristi Rawal, PhD
+18606908495
shristi.rawal@rutgers.edu
Archana Shrestha, PhD
+9779801002245
archana@kusms.edu.np
Isha Puuri
Nobel Medical College & Teaching Hospital
Interventions
  • Behavioral: MOM-HD — Participants will receive education and training on proper BP and/or BG monitoring and will be provided a BP monitor and/or glucometer with strips. They will be asked to use the MOM-HD mobile app to measure and record daily BP (until 6 weeks postpartum) and, for women with GDM, fasting and 2-hour postprandial BG (until delivery). Readings are automatically uploaded via Bluetooth to a provider portal and reviewed daily by a nurse. Participants will receive automated reminders, instant feedback on readings, and educational materials via the app. They will participate in biweekly tele-visits with a nurse to review readings, discuss symptoms, and receive counseling on lifestyle, diet, and care plans.
  • Other: Standard Care — Pregnant women with HDP and GDM will receive standard antenatal care, which includes more frequent hospital visits (6-8 extra), ultrasound, urine dipstick, BP/BG monitoring with paper record booklets, dietary and physical activity counseling, and OB/GYN follow-up. GDM patients will consult with a dietitian and physical therapist. Postpartum follow-up includes BP/BG testing at 6 weeks.
Study Locations (3 sites)
Nobel Medical College & Teaching Hospital, Biratnagar, Nepal
Dhulikhel Hospital, Dhulikhel, Nepal
Paropakar Maternity and Women's Hospital, Kathmandu, Nepal
Eligibility Criteria
Inclusion Criteria: * Pregnant women receiving antenatal care at RCT site * Diagnosed with one of the following: * Chronic hypertension (sustained systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or on antihypertensive treatment before 20 weeks of gestation) * Gestational hypertension or preeclampsia without severe features (sustained systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg after 20 weeks of gestation) * Gestational diabetes * Age 18 years or older * Access to a smartphone * Gestational age ≤ 34 weeks at enrollment * Able to read and write Exclusion Criteria: * Multifetal pregnancies * Apparent communication difficulties (e.g., hearing, speech, or cognitive impairments), as judged by research assistants * Unable to understand the Nepali language * Severe maternal illness or any condition that precludes active study participation (e.g., preeclampsia with severe features, eclampsia, HELLP syndrome, or other conditions requiring inpatient management) * Declines to provide informed consent
Conditions Eye Diseases, Visual Impairment, Glaucom...
Phase NA
Enrollment 900
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

To compare eye disease detection rates at a Federally Qualified Health Center between a technology-enhanced protocol and standard optometric clinical examination for three of the leading causes of blindness: glaucoma, diabetic retinopathy, and visually significant cataract.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Other: Standard optometric examination — Participants will see the optometrist at the Federally Qualified Health Center. The guidelines define usual care as: an in-person comprehensive eye examination with assessment of patient history, visual acuity, pupil examination, ocular motility and alignment, intraocular pressure, and biomicroscopy with additional tests, as appropriate. A glasses prescription will be given to the participant if needed. Participants will complete surveys at baseline before their eye exam and 6 weeks after the eye exam.
  • Other: Technology enhanced eye disease detection protocol — Participants will receive a technology enhanced eye disease detection protocol from ophthalmic technicians that includes measurements of visual function such as visual acuity, refraction, intraocular pressure, pachymetry, external eye and fundus photography, and optical coherence tomography of the macula and retinal nerve fiber layer. The optometrist at the Federally. Qualified Health Center will then use a protocol to grade the testing and identify eye disease. The results of the grading will inform whether the person receives a brief appointment with the optometrist (no disease detected) or an in-depth appointment with the optometrist (disease detected). During the first visit, participants receive care navigation support to purchase low-cost glasses from an on-line retailer. When participants return for the optometrist exam, glasses will be fit. Participants will receive care navigation support to attend any recommended specialty follow-up appointments.

Primary Outcomes

  • Rate of vision threatening eye disease (glaucoma/suspected glaucoma, visually significant cataract, diabetic retinopathy) (Visit 1(day 1))
  • Rate of glaucoma/suspected glaucoma (Visit 1 (Day 1))
  • Rate of visually significant cataract (Visit 1(day 1))
  • Rate of diabetic retinopathy (Visit 1(day 1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-04
Completion: 2030-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Collaborators: Centers for Disease Control and Prevention
Principal Investigators:
  • Paula Anne Newman-Casey, MD (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Suzanne Winter, MS
734-763-6967
wsuzanne@med.umich.edu
David Bush, OD
810-406-4246
david.bush@hamiltonchn.org
Hamilton Optometry Clinic
Paula Anne Newman-Casey, MD
Hamilton Optometry Clinic
Interventions
  • Other: Standard optometric examination — Participants will see the optometrist at the Federally Qualified Health Center. The guidelines define usual care as: an in-person comprehensive eye examination with assessment of patient history, visual acuity, pupil examination, ocular motility and alignment, intraocular pressure, and biomicroscopy with additional tests, as appropriate. A glasses prescription will be given to the participant if needed. Participants will complete surveys at baseline before their eye exam and 6 weeks after the eye exam.
  • Other: Technology enhanced eye disease detection protocol — Participants will receive a technology enhanced eye disease detection protocol from ophthalmic technicians that includes measurements of visual function such as visual acuity, refraction, intraocular pressure, pachymetry, external eye and fundus photography, and optical coherence tomography of the macula and retinal nerve fiber layer. The optometrist at the Federally. Qualified Health Center will then use a protocol to grade the testing and identify eye disease. The results of the grading will inform whether the person receives a brief appointment with the optometrist (no disease detected) or an in-depth appointment with the optometrist (disease detected). During the first visit, participants receive care navigation support to purchase low-cost glasses from an on-line retailer. When participants return for the optometrist exam, glasses will be fit. Participants will receive care navigation support to attend any recommended specialty follow-up appointments.
Study Locations (1 sites)
Hamilton Optometry Clinic, Flint, Michigan 48505. United States
Eligibility Criteria
Inclusion Criteria: • Speak English, Spanish, Arabic, Chinese, French, Hindi, Finnish, Albanian, Russian or Tagalog Exclusion Criteria: * significant eye pain * sudden decrease in vision within one week * binocular diplopia * cognitive impairment * pregnancy * previously declined participation
Conditions Glaucoma
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

The current situation outside of large cities in lower-income countries, as described above, is suboptimal for the diagnosis of glaucoma. Doctors have no means of assessing visual fields, and as such may not be able to identify the condition until too advanced for any meaningful intervention (ie, to enable preservation of vision). Vision loss from glaucoma is irreversible. Understanding, through this pilot study, how well the World Sight Foundation Field Machine (WSFFM) works is an essential step towards trialling its use in lower-income countries. The justification for enabling this is to allow clinicians in the developing world to make more informed assessments of their glaucoma patient's status; this should translate in more timely treatments or referral for further investigation before further irreversible vision loss. The WSFFM will be compared to the Humphrey Visual Field (HVF) analyser. The HVF analyser is the gold standard method of measuring visual fields; in our hospital eye service it is almost exclusively the method used, and as such the field technicians are particularly skilled in their use. The output data of the HVF enables easy quantification of level of field loss; by comparing the output from the WSFFM it would be possible to allow some form of quantification against "the standard" such that an idea of how well it works may be calculated.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: World Sight Foundation Field Machine — Test Intervention
  • Other: Comparator — Gold Standard of Care (Comparator)

Primary Outcomes

  • Validation of the WSFFM - comparing the visual field testing obtained with WSFFM and HVF analyser. (Day 1)
  • Feasibility of using the WSFFM in a "real-life" setting (Day 1)
  • Validation of the WSFFM - comparing the visual field testing obtained with WSFFM and HVF analyser. (Day 1)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-29
Completion: 2026-07-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Buckinghamshire Healthcare NHS Trust
Contact Information
Study Contact:
James Cooper
07816020305
james.cooper9@nhs.net
Matthew Kinsella, MD
+441296 831378
bht.research@nhs.net
Buckinghamshire Healthcare NHS Trust
James Cooper, BSc, MSc
+441296 831378
james.cooper9@nhs.net
Buckinghamshire Healthcare NHS Trust
Interventions
  • Device: World Sight Foundation Field Machine — Test Intervention
  • Other: Comparator — Gold Standard of Care (Comparator)
Study Locations (1 sites)
Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom
Eligibility Criteria
Inclusion Criteria: * \- Patients attending glaucoma outpatient clinic * Patients requiring visual field testing, with plan for "SITA-STANDARD" HVF testing * Patients 18 years or older and of any gender * Patients capable of giving informed consent. Exclusion Criteria: * \- Patients not requiring visual field testing on that outpatient clinic attendance. * Patients requiring visual field testing, with plan for "SITA-FAST" or "SITA-FASTER" HVF testing. * Patients who do not attend their outpatient clinic appointment, * Patients not able to perform visual field testing (for example due to their visual acuity, physical difficulty in positioning for test duration, or cognitive difficulties in understanding instructions). * Patients under the age of 18 years old.
Conditions Idiopathic Intracranial Hypertension (II...
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This will be a randomized, double-blind, parallel, placebo-controlled trial of 60 participants. The primary analysis will be a statistical comparison of the estimates of the mean difference in the 12-month change in intracranial pressure (ICP) between participants assigned to the tirzepatide and Placebo arms in 1:1 randomization using the intention-to-treat (ITT) population. Hypothesis testing will be performed using analysis of covariance (ANCOVA), with the treatment indicator as the independent variable and the 12-month change in ICP as the dependent variable. Models will include baseline ICP as a covariate. This primary endpoint will use a significance level of 0.05 to declare significance.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Tirzepatide — Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
  • Drug: Tirzepatide Placebo — Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months

Primary Outcomes

  • Change in intracranial pressure in Idiopathic Intracranial Hypertension (IIH) patients (From enrollment to end of treatment at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-25
Completion: 2028-08
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: Eli Lilly and Company
Principal Investigators:
  • Alexa N Bramall, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Alexa N Bramall, MD
919-660-1754
alexa.bramall@duke.edu
Beth Perry, RN
919-681-2695
beth.perry@duke.edu
Alexa N Bramall, MD
919-660-1754
alexa.bramall@duke.edu
Duke University Medical Center
Interventions
  • Drug: Tirzepatide — Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
  • Drug: Tirzepatide Placebo — Dosage Treatment time 2.5mg/0.5mL: 4 Weeks 5mg/0.5mL: 4 Weeks 7.5mg/0.5mL: 4 Weeks 10mg/0.5mL: 4 Weeks 12.5mg/0.5mL: 4 weeks 15mg/0.5 mL: 7 Months
Study Locations (1 sites)
Duke University Medical Center, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria: 1. Signs and symptoms of increased intracranial pressure: 1. headaches, tinnitus, visual obscurations, papilledema; 2. absence of localizing findings on neurological examination (except for VI nerve palsy); 3. no secondary causes identified on imaging, e.g., hydrocephalus, space- occupying lesion; 4. elevated lumbar puncture (LP) opening pressure (OP) ≥25 cm H2O in lateral decubitus position with legs extended (\>= (≥ 20cm H2O if one of the following is present: pulse synchronous tinnitus, abducens palsy, Frisen grade II papilledema, transverse venous sinus stenosis, partially empty sella or enlarged optic nerve sheath on magnetic resonance imaging (MRI); 5. the patient is awake and alert. 2. BMI ≥30 kg/m2 3. Age 18-60 years of age 4. Unilateral or bilateral papilledema 5. Able to provide informed consent 6. Women of child-bearing age must use birth control (non-oral contraceptive method or add a barrier method of contraception). Exclusion Criteria: 1. Previous bariatric surgery 2. Prior intervention for high ICP including optic nerve sheath fenestration (ONSF), venous stenting and/or shunting 3. Taking another GLP-1 agonist, another drug that can interfere with the GLP-1 agonist, or any other anti-obesity medication 4. History of pancreatitis, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), history of gallbladder disease, ulcerative colitis, Crohn's disease, or history of hypersensitivity reaction in response to the drug 5. Pregnancy or planning a pregnancy in the next 12 months or currently breastfeeding 6. Other disorders causing visual loss and/or anomalous optic nerve 7. Taking another medication to lower ICP in IIH (if previously taking another medication for ICP must be off this medication for at least 30 days prior to enrollment) 8. No change in headache medications in the past 60 days 9. Venous sinus thrombosis on magnetic resonance venography (MRV) 10. Papilledema Frisen Grade III, IV or fulminant IIH 11. Mean perimetric deviation ≤ -7 dB 12. CSF contents outside of normal limits 13. Uncontrolled hypertension (≥140mmHg/90 mmHg) 14. Anemia (hemoglobin \[Hgb\] ≤ 8.0g/dL) 15. Diagnosed sleep apnea with continuous positive airway pressure (CPAP) use 16. Exposure to a drug, substance, or disorder that has been associated with elevation of intracranial pressure within 2 months of diagnosis such as lithium, vitamin A, various cyclines 17. eGFR \< 30 ml/min/1.73m2 18. Type II diabetes
Conditions Pulmonary Arterial Hypertension, Pulmona...
Phase NA
Enrollment 30
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Aria CV Pulmonary Hypertension System — The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.

Primary Outcomes

  • Primary Safety Endpoint is the incidence of investigational device- or procedure-related serious adverse events (SAEs). (30 days post-implant)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-03-15
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Aria CV, Inc
Principal Investigators:
  • Ashwin Ravichandran, M.D. (PRINCIPAL_INVESTIGATOR) - Ascension Health
  • Jim White, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - University of Rochester
Contact Information
Study Contact:
Caytie Longhenry
651-200-4891
clonghenry@ariacv.com
VP of Clinical
Lloyd Liang
LLLiang@mednet.ucla.edu
University of California-Los Angeles
Interventions
  • Device: Aria CV Pulmonary Hypertension System — The Aria CV PH System is indicated for the treatment of adult patients diagnosed with Pulmonary Hypertension in World Health Organization (WHO) Groups I, II, and III who remain symptomatic despite treatment with optimal medical therapy.
Study Locations (12 sites)
University of California - San Diego, La Jolla, California 92093 United States
University of California-Los Angeles, Los Angeles, California 90095 United States
St. Vincent Health, Indianapolis, Indiana 46260 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
University of Minnesota, Minneapolis, Minnesota 55435 United States
Mayo Clinic, Rochester, Minnesota 55905 United States
Cornell University, New York, New York 10065 United States
University of Rochester, New York, New York 14627 United States
The Christ Hospital, Cincinnati, Ohio 45219 United States
Ohio Health, Columbus, Ohio 43214 United States
Eligibility Criteria
Common Inclusion Criteria: 1. 18 years of age or older. 2. Mean pulmonary artery pressure (mPAP) \> 25mmHg. 3. Right heart dysfunction as evidence by at least one of the following: 1. Tricuspid Annulus Plan Systolic Excursion (TAPSE) ≤ 16mm 2. RV Fractional area change \< 35% 3. RV systolic velocity \< 11.5 cm/s 4. RV free wall strain \< 18% 5. Lateral tricuspid annulus peak systolic velocity (S') \< 9cm/s 4. Pulmonary compliance (C) \< 3.0 ml/mmHg 5. Current assessment of WHO FC III or ambulatory IV 6. Main pulmonary artery (MPA) diameter and anatomy suitable for placement of the device as defined in the Instructions For Use (IFU) and as assessed by multi-slice computed tomography (MSCT). 7. Subject is deemed appropriate for Aria CV device by the Subject Care Team at the investigation site and approved by the Eligibility Review Committee (ERC). 8. The subject has agreed to participate in the study by signing the study specific informed consent form. 9. The subject agrees to abide by device related travel restrictions. Unique Inclusion Criteria for WHO Group I: 10. Pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg 11. Pulmonary vascular resistance (PVR) \> 3 Woods Units (WU) 12. The subject remains symptomatic despite being on a stable drug regimen of PH specific medication(s) appropriate for their PH classification for at least 90 days prior to planned index procedure. Unique Inclusion Criteria for WHO Group II: 10\. Previous diagnosis of heart failure with preserved ejection fraction (HFpEF) (ejection fraction ≥ 50%) 11. PCWP \> 15 mmHg 12. PVR \> 3 WU Unique Inclusion Criteria for WHO Group III: 10\. Previous diagnosis of lung disease, including but not limited to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) including idiopathic pulmonary fibrosis (IPF) or combined emphysema with fibrosis. 11\. PCWP ≤ 15mmHg 12. PVR \>4 WU Common Exclusion Criteria: 1. Diagnosis of WHO Groups 4 or 5 PH. 2. Recent clinical event(s) of any of the following: 1. Myocardial infarction or stroke within 6 months prior to the index procedure; 2. Sustained tachyarrhythmia (documented heart rate \>110/min) within 2 months prior to the index procedure; 3. Uncontrolled, chronic atrial fibrillation. 3. Pre-existing or requirement of emergent surgery/ intervention, or implantation of prosthetic cardiac device that, in the opinion of the investigator, may interfere with Aria CV PH System placement or function. 4. Any of the following medical history or comorbidities: a. History of endocarditis; b. History of unprovoked Pulmonary Embolism; c. Current renal insufficiency as demonstrated by an eGFR \< 30 mL/min/1.73 m2 or end stage renal disease requiring chronic dialysis; d. Current diagnosis of scleroderma associated with: i. Any history of GI bleeding or receiving iron infusions within 2 years prior to enrollment; ii. Significant skin involvement that could compromise daily activities or the ability to receive IV medications, or sclerodactyly that causes surface ulcerations, digital ulcerations, or ulcerating calcinosis lesions. e. History of receiving immunosuppressant therapy as follows: i. Excluded if receiving Mycophenolate mofetil within 30 days prior to enrollment, or Rituximab within 6 months prior to enrollment, or currently receiving Prednisone at a dose \> 12 mg per day at time of enrollment; ii. Excluded if any immunosuppressant other than Mycophenolate mofetil, Rituximab or Prednisone, per above. e. Current pulmonary veno-occlusive disease (PVOD); f. Current pulmonary capillary hemangiomatosis (PCH); g. History of clinically significant patent foramen ovale (PFO) or other inter-atrial or inter-ventricular shunt; h. History of gastric antral vascular ectasia (GAVE), gastrointestinal or intracranial bleeding which, in the opinion of the investigator, will predispose subject to major bleeding events following Aria CV device placement and warfarin anticoagulation regimen; i. Active infection requiring antibiotic therapy within two (2) weeks of procedure; j. Blood dyscrasias that may, in the opinion of investigator(s), expose subject to unacceptable procedural risks such as severe or worsening leukopenia, anemia, thrombocytopenia, untreated iron deficiency or history of bleeding diathesis or coagulopathy. 5. Anatomy is not suitable for placement of Aria CV device. 6. Right heart valve regurgitation as follows: 1. Moderate to severe (Grade 3 or 4) pulmonary valve regurgitation; 2. Severe (Grade 4) tricuspid valve regurgitation. 7. Hypersensitivity or contraindication to: 1. Required medications (e.g., contrast agents, warfarin, heparin) which cannot be adequately managed; 2. Materials in device including polyurethane, silicone, nickel, and titanium. 8. Ineligible for or refuses blood transfusion. 9. Pregnant, nursing or is planning to become pregnant in the next two years. 10. Life expectancy of less than two years. 11. Currently participating in or planning to participate in other investigational study that may interfere with the outcome of this study. 12. For subject on supplemental oxygen therapy - Subject adheres to the treatment regimen that in the opinion of the physician does not increase subject's safety. 13. Previous diagnosis of cardiac amyloidosis. Unique Exclusion Criteria for WHO Group I: N/A Unique Exclusion Criteria for WHO Group II: 1. Previous diagnosis of idiopathic hypertrophic subaortic stenosis (IHSS, also known as hypertrophic obstructive cardiomyopathy - HOCM). 2. Untreated severe aortic or mitral stenosis 3. Diagnosis of heart failure with reduced ejection fraction (HFrEF) 4. Previous diagnosis of nonobstructive hypertrophic cardiomyopathy. Unique Exclusion Criteria for WHO Group III: N/A
Conditions Primary Open Angle Glaucoma, Glaucoma, P...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective Laser Trabeculoplasty (DSLT) represents a potential surgical alternative for managing IOP in patients with naive, untreated glaucoma. This study aims to evaluate the efficacy of DSLT in achieving significant IOP reduction without the need for postoperative medications. Unmet Medical Need: Overview of DSLT Direct Selective Laser Trabeculoplasty (DSLT) is an emerging technology in glaucoma management that combines laser techniques to reduce intraocular pressure (IOP). While it works off the auspices of a previous technology (SLT), the method of delivery is significantly different. Current Research Landscape Most existing studies focus on patients who have already received other forms of treatment or who have more advanced glaucoma. This creates an unmet need to evaluate how DSLT can be effectively integrated into the management of patients at the very beginning of their glaucoma journey. Understanding its efficacy in this population is crucial for establishing best practices and improving long-term outcomes. Interventional Glaucoma Management vs. Standard of Care Standard of care for newly diagnosed glaucoma typically involves medications, such as topical prostaglandin analogs, which can have side effects and may not be effective for all patients. In contrast, interventional glaucoma management-such as DSLT-offers a potentially more direct approach to lowering IOP without the need for ongoing medication. Investigating DSLT in this context could lead to a paradigm shift in how newly diagnosed patients are managed, reducing their reliance on medications and potentially improving adherence and quality of life. Conclusion Addressing this research gap will not only help clarify the role of DSLT in early glaucoma management but could also enhance patient outcomes and guide future treatment protocols. Focusing on newly diagnosed patients is essential for determining the long-term benefits and risks associated with this innovative technology.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Direct Selective Laser Trabuloplasty — Eligible participants will undergo the DSLT procedure to facilitate controlled aqueous outflow. DSLT will consist of 120 shots, 400 µm spot size, energy 1.4-1.8 mJ delivered at the limbus over 2.4 seconds

Primary Outcomes

  • Percent Reduction in IOP from baseline at 6 months (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2002-03-11
Completion: 2026-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brian Shafer
Contact Information
Study Contact:
Brian Shafer, MD
2672102169
brian.shafer@shafervision.com
Brian Shafer, MD
2156542020
brian.shafer@shafervision.com
Shafer Vision Institute
Morgan O'Brien
215 654 2020
morgan@shafervision.com
Shafer Vision Institute
Interventions
  • Device: Direct Selective Laser Trabuloplasty — Eligible participants will undergo the DSLT procedure to facilitate controlled aqueous outflow. DSLT will consist of 120 shots, 400 µm spot size, energy 1.4-1.8 mJ delivered at the limbus over 2.4 seconds
Study Locations (1 sites)
Shafer Vision Institute, Plymouth Meeting, Pennsylvania 19462 United States
Eligibility Criteria
Inclusion Criteria: Adults aged 18 years or older: Participants must be adults, aged 18 years or older, to ensure they are capable of providing informed consent and to focus on adult-onset glaucoma. This age threshold allows the study to target a population where open-angle glaucoma typically manifests, avoiding potential variations in outcomes that might arise in younger populations with different types of ocular conditions. Diagnosis of naive, untreated open-angle glaucoma or similar conditions: The study is restricted to individuals who have been newly diagnosed with primary open-angle glaucoma and have not yet received any form of treatment, either pharmacological or surgical. This ensures that the effects of DSLT (Direct Selective Laser Trabeculoplasty) are evaluated without the confounding influence of prior treatments. Other similar conditions may include ocular hypertension or other early-stage glaucomatous conditions where IOP reduction is indicated (ie: pigment dispersion syndrome/glaucoma and pseudoexfoliation). This broadens the inclusion slightly to capture patients with conditions that have a similar disease mechanism and treatment goal, without including those with more complex or mixed forms of glaucoma. Exclusion Criteria: Previous glaucoma surgeries/interventions: Patients who have undergone prior glaucoma-related surgeries (e.g., trabeculectomy, laser trabeculoplasty, or shunt procedures) or received other significant glaucoma interventions (such as long-term glaucoma medication use) are excluded. This criterion ensures the study evaluates the effect of DSLT in a treatment-naive population. Prior surgeries or interventions could bias the results by introducing variability in eye physiology, making it difficult to attribute outcomes solely to DSLT. Secondary glaucoma or other significant ocular conditions: Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases, are excluded. These conditions often have different pathophysiological mechanisms, which could lead to varied responses to DSLT. Other significant ocular conditions that could interfere with the study include advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function. Excluding these conditions ensures a clearer evaluation of DSLT's effects on open-angle glaucoma without interference from unrelated ocular abnormalities. 3\. Patients who are unable to fixate their head and/or eyes, such as patients suffering from uncontrolled nystagmus, tremors, or similar conditions. 4\. Patients with a pupil that cannot constrict to a diameter of 4 mm or less. In summary, these criteria focus on a specific and controlled population of treatment-naive glaucoma patients to provide a clean evaluation of the effectiveness and safety of DSLT, while excluding individuals whose prior treatments or other conditions could skew the results.
Conditions Glaucoma
Phase NA
Enrollment 245
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: iStent Infinite — iStent Infinite Trabecular Micro-Bypass System

Primary Outcomes

  • Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline (12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-01
Completion: 2027-08
Eligibility
Age: 35 Years and older
Sex: ALL
Volunteers: false
Enrollment: 245 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Glaukos Corporation
Contact Information
Study Contact:
Dari Parizadeh
949-481-0575
dparizadeh@glaukos.com
Kerry Stephens
949-481-8057
kstephens@glaukos.com
Dari Parizadeh
Glaukos Investigator Site
Interventions
  • Device: iStent Infinite — iStent Infinite Trabecular Micro-Bypass System
Study Locations (1 sites)
Glaukos Investigator Site, Cincinnati, Ohio 45242 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary open-angle glaucoma * Phakic or pseudophakic * Age 35 years or older Exclusion Criteria: * Traumatic, uveitic, neovascular, angle-closure glaucoma or * glaucoma associated with vascular disorders * Active corneal inflammation or edema * Retinal disorders not associated with glaucoma
Conditions ESR1 Gene Mutation, Advanced Breast Canc...
Phase Not Applicable
Enrollment 450
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, non-interventional real-world study to observe the efficacy and safety of different treatment regimens in patients with ESR1-mutated HR+/HER2-advanced breast cancer after failure of endocrine therapy. Epidemiological data, efficacy and safety measures will be collected for each subject. Data on efficacy and safety assessment indicators will be collected every 2-3 months until disease progression, receipt of a new anti-tumour treatment modality, death, loss to follow-up, and arrival at the data collection cut-off date. The cut-off date for data collection is defined as 8 weeks after completion of 6 visits for each subject, or 4 weeks after treatment discontinuation and subject discontinuation/withdrawal. Subjects receiving a different treatment regimen remained subject to assessment of safety indicators 4 weeks after discontinuation of the original treatment regimen.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Endocrine therapy — All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
  • Drug: Chemotherapy Prednisone — All chemotherapy treatment regimens approved for advanced breast cancer

Primary Outcomes

  • PFS (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-08
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SciClone Pharmaceuticals
Contact Information
Study Contact:
Chunyang Li
86-15216717343
lichunyang@sciclone.com
Chunyang Li, Doctor
86-15216717343
lichunyang@sciclone.com
Tianjin Haidafu Internet Hospital
Interventions
  • Drug: Endocrine therapy — All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
  • Drug: Chemotherapy Prednisone — All chemotherapy treatment regimens approved for advanced breast cancer
Study Locations (1 sites)
Tianjin Haidafu Internet Hospital, Suzhou, Jiangsu China
Eligibility Criteria
Inclusion Criteria: * 1\. must have a histologically or cytologically confirmed diagnosis of breast cancer with evidence of locally advanced disease unsuitable for excision or radical radiotherapy, or evidence of metastatic disease unsuitable for radical treatment. * 2\. female ≥ 18 years of age * 3\. female subjects must be postmenopausal (meeting any of the following criteria is sufficient) a) Has undergone oophorectomy. b) Age ≥ 60 years. c) 40 years old \< age ≤ 60 years old with 1 year of menopause. d) Age \<60 years and receiving ovarian suppression therapy. * 4\. ER-positive and HER2-negative status and ESR1-mutation positive must be confirmed. * 5\. must have progressed on at least one line of endocrine therapy prior to enrollment, including monotherapy or combination therapy. * 6\. have normal organ function (as assessed by the investigator). Exclusion Criteria: * 1\. women who are pregnant or breastfeeding * 2\. known difficulties in tolerating oral medications, or conditions that interfere with the absorption of oral medications or allergies to medications and their excitements * 3\. other conditions that make enrollment in the study unsuitable, at the discretion of the investigator
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE3
Enrollment 115
Locations 58 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-23
Study Details Design, interventions, and primary outcomes

About This Study

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo blood and CSF sample collection
  • Procedure: Computed Tomography — Undergo CT or PET/CT
  • Radiation: Involved-Field Radiation Therapy — Undergo IFRT
  • Procedure: Lumbar Puncture — Undergo LP
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Procedure: Positron Emission Tomography — Undergo PET/CT
  • Radiation: Proton Beam Craniospinal Irradiation — Undergo pCSI
  • Other: Quality-of-Life Assessment — Ancillary studies

Primary Outcomes

  • Overall survival (OS) (From randomization until death due to any cause, assessed up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-04
Completion: 2033-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 115 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NRG Oncology
Principal Investigators:
  • Jonathan T Yang (PRINCIPAL_INVESTIGATOR) - NRG Oncology
Contact Information
Study Contact:
Site Public Contact
855-776-0015
Mayo Clinic Hospital in Arizona
Eric Lehrer
Mayo Clinic Hospital in Arizona
Site Public Contact
501-686-8274
University of Arkansas for Medical Sciences
Interventions
  • Procedure: Biospecimen Collection — Undergo blood and CSF sample collection
  • Procedure: Computed Tomography — Undergo CT or PET/CT
  • Radiation: Involved-Field Radiation Therapy — Undergo IFRT
  • Procedure: Lumbar Puncture — Undergo LP
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
Study Locations (58 sites)
Mayo Clinic Hospital in Arizona, Phoenix, Arizona 85054 United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
UC San Diego Health System - Encinitas, Encinitas, California 92024 United States
UC San Diego Moores Cancer Center, La Jolla, California 92093 United States
UC San Diego Medical Center - Hillcrest, San Diego, California 92103 United States
California Protons Cancer Therapy Center, San Diego, California 92121 United States
Sibley Memorial Hospital, Washington D.C., District of Columbia 20016 United States
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida 33180 United States
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida 33146 United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida 33442 United States
Eligibility Criteria
Inclusion Criteria: * PRIOR TO STEP 1 REGISTRATION * Patients with pathologically (histologically or cytologically) proven diagnosis of breast cancer or NSCLC * Patients must have newly diagnosed leptomeningeal metastasis established through at least one of the following: * Positive CSF cytology for malignancy * CSF cytology with suspicious cells is considered positive; CSF cytology with atypical cells is considered equivocal and not positive * Patients with an equivocal or negative CSF cytology result, or not suitable for CSF sampling, radiographic diagnosis of leptomeningeal metastasis with linear and/or nodular disease and documentation of typical clinical signs (European Association of Neuro-Oncology \[EANO\]-European Society for Medical Oncology \[ESMO\] Diagnostic Criteria Type IIA-IIC) is required * Patients with typical clinical signs of leptomeningeal metastasis may have one or more of the following symptoms and signs: headache, nausea, vomiting, mental status change, gait difficulty, cranial nerve palsy, diplopia, visual change, hearing loss, radicular weakness, radicular sensory change, urinary retention, saddle anesthesia, constipation, neck pain, and back pain * For patients with prior history of immunotherapy or current immunotherapy, CSF sampling rather than just MRI enhancement is strongly recommended to exclude immune-related aseptic meningitis * Patients must be candidates for radiation therapy for the treatment of leptomeningeal metastasis * Age ≥ 18 * PRIOR TO STEP 2 REGISTRATION * Note: Step 2 registration must occur no later than 30 calendar days after step 1 registration * Financial clearance for proton therapy treatment * Patients must have systemic disease evaluation through standard of care imaging for example CT chest/abdomen/pelvis or body PET/CT * Karnofsky performance status ≥ 60 * Not pregnant and not nursing * Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal * Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 8.0 g/dl is acceptable) * Absolute neutrophil count (ANC) ≥ 1,000/mm\^3 (Note: the use of granulocyte-colony stimulating factor or other intervention to achieve ANC ≥ 1,000/mm\^3 is acceptable) * Platelets ≥ 100,000/mm\^3 (Note: the use of transfusion or other intervention to achieve platelets ≥ 100,000/mm\^3 is acceptable) * Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) (patients with known Gilbert disease without other clinically significant liver abnormalities are not excluded) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine transaminase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 × ULN * No prior radiation therapy to the spinal cord with equivalent dose in 2 gray (Gy) fractions (EQD2) more than 40Gy or cauda equina with EQD2 more than 50Gy using alpha/beta ratio of 3 * No prior treatment for leptomeningeal metastasis (note: prior CNS treatment for other non-leptomeningeal disease is allowed) * No history of unstable angina requiring hospitalization in the last 3 months * No history of myocardial infarction within the last 3 months * New York Heart Association Functional Classification II or better (New York Heart Association \[NYHA\] Functional Classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.) * No active infection currently requiring intravenous (IV) antibiotic management * No active chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy * No CTCAE v5.0 ≥ grade 2 encephalopathy